Wegovy 2.4mg weight loss: what really happens at the maintenance dose

The biggest myth about 2.4mg Wegovy: that it works the moment you reach it

Many people starting Wegovy assume that 2.4mg is the destination, and that weight loss on 2.4mg Wegovy begins the moment the dose changes. In reality, the dose is stepped up gradually over several months precisely because the body needs time to adjust. Moving through 0.25mg, 0.5mg, the 1mg stage, where many people begin to notice meaningful appetite changes, and 1.7mg before arriving at 2.4mg is not a delay; it is the mechanism working as intended. Nausea and other gastrointestinal symptoms are most common in the early weeks and tend to ease as each dose level becomes familiar.

The clinical evidence on how Wegovy works reflects this pacing. The STEP 1 trial (the foundational study for the 2.4mg licence) ran for 68 weeks and built its results across the full titration period, not just the weeks spent at the maintenance dose. Expecting a sudden step-change in results at 2.4mg misreads how semaglutide's appetite-reducing and gastric-slowing effects accumulate over time.

What does tend to happen at 2.4mg is that appetite suppression becomes more consistent and the satiety signals after meals become easier to recognise. How much weight that translates to depends heavily on what someone was losing before, their baseline, and how closely they can follow the lifestyle support that accompanied participants in the trials. The prescriber who oversees your treatment is the right person to interpret your individual progress at this stage.

What the trial data actually shows about weight loss on 2.4mg Wegovy

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight plus a weight-related condition, none of whom had type 2 diabetes. After 68 weeks, the group receiving 2.4mg semaglutide weekly lost an average of about 15% of body weight. Roughly one in three participants lost more than 20%. The placebo group lost around 2.4%.

Those are averages. Some people lose considerably more; others lose less. Age, sex, baseline weight, adherence to lifestyle changes, and how the body responds to GLP-1 receptor agonism all play a role. The trial data gives a reliable population-level picture, but a prescriber looking at your specific situation (your starting point, your comorbidities, how your body has responded at each titration step) is the only one who can tell you what a realistic trajectory looks like for you.

For context on how the 2.4mg level compares with lower doses during titration, the 1.7mg versus 2.4mg comparison is worth reading. The difference in average results between those two doses is meaningful but not dramatic; for some people, 1.7mg turns out to be the highest tolerated dose, which is a clinical decision, not a failure.

It is also worth knowing that the MHRA has since approved a 7.2mg maintenance dose, with a dedicated single-dose pen confirmed on 14 April 2026. Early data suggested around 20.7% average weight loss at 72 weeks at 7.2mg. The full Wegovy dose schedule covers this in detail.

Side effects at the 2.4mg dose and when to seek help

The side-effect profile at 2.4mg mirrors the general GLP-1 pattern but can be more noticeable than at lower doses, particularly in the first few weeks after the increase. Nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported. Most people find these settle within a couple of weeks. Staying well hydrated, eating smaller meals and avoiding high-fat foods around the time of injection can help.

The side effects worth knowing urgently about are less common but more serious. In January 2026, the MHRA's Drug Safety Update drew attention to acute pancreatitis across GLP-1 medicines: severe stomach pain that is persistent and radiates to the back (with or without vomiting) is a signal to stop the injection and seek emergency medical care. Gallbladder-related pain and signs of serious dehydration after prolonged vomiting or diarrhoea also warrant prompt attention rather than waiting for the next scheduled check-in.

Any suspected side effects, including unexpected ones, can be reported directly to the MHRA via the Yellow Card scheme. If you have questions about a symptom between scheduled reviews, the aftercare team at your prescribing pharmacy is the practical first call. At nume (at our contact page) prescriber support is available seven days a week specifically for this.

Who reaches 2.4mg and what happens with NHS versus private access

Under Wegovy's UK licence, 2.4mg is available to adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds of 2.5 kg/m² apply for adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Reaching 2.4mg always requires clinical assessment at each titration step, a prescriber reviews progress and, if needed, holds someone at a lower dose before moving up.

On the NHS, Wegovy is commissioned through specialist weight management services under NICE guidance TA875, which limits treatment to a maximum of two years and requires involvement of a multidisciplinary team. Waiting lists are frequently long. Private routes through a GPhC-registered pharmacy do not require a referral, though the same clinical eligibility applies and every prescription is reviewed by a GPhC-registered Independent Prescriber before dispensing.

If you are comparing private costs, the Wegovy price comparison page sets out what to look for in a quoted price and what is typically not included. A treatment price should cover clinical review, prescription and aftercare, not just the pen itself.

Treatment starts at 0.25mg for a reason, the early dose stages matter for tolerability, and skipping them is not something a legitimate prescriber will do. When your pen does arrive, it comes in plain, unbranded packaging via tracked DPD delivery, and each KwikPen is designed to be injected once weekly at home. Check your eligibility for treatment below if you are considering starting.